Adamas Announces New Employment Inducement Grant
February 08, 2019 18:49 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Announces New Employment Inducement Grant
January 10, 2019 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
January 06, 2019 11:38 ET
|
Adamas Pharmaceuticals, Inc.
-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700...
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
December 18, 2018 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Present at Three November Investor Conferences
November 09, 2018 13:49 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Reports Third Quarter 2018 Financial Results
November 01, 2018 16:01 ET
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...
Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
October 26, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
October 08, 2018 08:30 ET
|
Adamas Pharmaceuticals, Inc.
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two yearsResults show a comparable 35% reduction from baseline in dyskinesia and OFF...
Adamas Announces New Employment Inducement Grant
October 05, 2018 17:51 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...